| Literature DB >> 17116432 |
Abstract
The ultimate goal of proteomics is to identify biologically active proteins and to produce them using biotechnology tools such as bacterial hosts. However, proteins produced by Escherichia coli must be refolded to their native state. Protein folding liquid chromatography (PFLC) is a new method developed in recent years, and it is widely used in molecular biology and biotechnology. In this paper, the new method, PFLC is introduced and its recent development is reviewed. In addition the paper includes definitions, advantages, principles, applications for both laboratory and large scales, apparatus, and effecting factors of PFLC. In addition, the role of this method in the future is examined.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17116432 PMCID: PMC7105250 DOI: 10.1016/j.jchromb.2006.10.068
Source DB: PubMed Journal: J Chromatogr B Analyt Technol Biomed Life Sci ISSN: 1570-0232 Impact factor: 3.205
Fig. 1Scheme of an ideal protein folding liquid chromatography having four functions simultaneously [3]. Four functions: removal of denaturants, refolding of target proteins, separation from contaminant proteins including misfolded intermediates of the target protein, and easy recovery of denaturants.
Examples of refolding of proteins by SEC
| Refolding proteins | Type of gel | Results of refolding | Years | Reference |
|---|---|---|---|---|
| Bovine serum albumin ribonuclease A lysozyme | Shimadzu diol 150 | 1992 | ||
| Superdex 75 | 60% | 1994 | ||
| rhETS-1 | Sephacryl S 100 | 71% | 1994 | |
| RNase | Sephacryl S 100 | >90% | 1994 | |
| Bovine carbonic anhydrase | Sephacryl S 100 HR | 56% | 1996 | |
| Lysozyme | Sephacryl S 100 HR | Activity recovery was 46% at a protein concentration of 80 mg/mL | 1996 | |
| Recombinant interlukin-6 | Superdex G-25 | Activity recovery was 17% | 1999 | |
| Recombinant lysozyme | Sephacryl S 100 | Activity recovery was 35% | 1999 | |
| Heterodimeric platelet-derived growth factor | Superdex 75 | Activity recovery was more than 75% | 1999 | |
| Lysozyme | Superdex 75 | Activity recovery was 90% at a protein concentration of 17 mg/mL | 2001 | |
| Urokinase plasminogen activator | Sephacryl S 300 | Activity was more than 5 times of dilution method | 2000 | |
| Lysozyme | Sephacryl S 100 | Activity recovery was near 100% at a concentration of 40 mg/mL | 2001 | |
| Urokinase plasminogen activator fragment | Sephacryl S 300 | Activity recovery was 15.3% | 2000 | |
| Lysozyme | Sephacryl S 100 | Activity recovery was 80% | 2002 | |
| Lysozyme | Superdex 75 HR | Activity recovery was >90% | 2003 | |
| Bovine carbonic anhydrase B | Superdex 75 | Activity recovery was 85% | 2003 | |
| recombinant | Sephacryl S 200 | Refolding yield was 14% | 2005 | |
| B lymphocyte stimulator | Sephacryl S 200 | Refolding yield was 30% | 2005 | |
| Lysozyme | Superdex 75 HR | Activity recovery was nearly 100% | 2006 | |
| Lysozyme | Sephacryl S 100 | Refolding yield was 96% | 2006 | |
| rhG-CSF | Superdex 75 | Specific activity was 1.2 × 108 IU/mg, mass recovery was 30% | 2006 |
Examples of protein refolding by HIC
| Refolding proteins | Refolding results | Years | References |
|---|---|---|---|
| rhIFN-γ | Activity recovery was 2–3 times of dilution method, purity was more than 85% | 1991, 1992 | |
| HIV protease mutants | 1997, 1998 | ||
| Bovine insulin | Refolding yield was 66% | 2002 | |
| Recombinant bovine | Mass recovery was | 2004 | |
| Prion protein | 87%, purity was 96% | ||
| Recombinant | Mass recovery was | 2003 | |
| Human proinsulin | 94%, purity was 90% | ||
| rhIFN-γ | Activity recovery was 2–3 times of dilution method | 2001 | |
| Lysozyme | Activity recovery was 94.6% | 2003 | |
| rhIFN-γ | Specific activity was 1.3 × 108 IU/mg, purity was >95% | 2004 | |
| Recombinant human stem cell factor | Purity was 94%, specific activity of 1.2 × 106 IU/mg | 2006 | |
| rhIFN-γ | Injection mass was about 2.0 g, injection volume was 700 mL, purity was >95%, specific activity was 5.7 × 107 IU/mg | 2002 | |
| rhG-CSF | Injection mass was about 1.5 g, injection volume was 200 mL, purity was 95.4%, specific activity was 2.3 × 108 IU/mg, mass recovery was 36.9% | 2006 | |
| C-IFN | Mass recovery was more than 80% | 2006 |
Examples for protein refolding by IEC
| Proteins | Stationary phases | Refolding results | Years | References |
|---|---|---|---|---|
| Cytochrome | CM-cellulose | Mass recovery was more than 80% | 1986 | |
| Ovalbumin | DEAE-cellulose | Refolding yield was 50% | 1990 | |
| Trypsin inhibitor | CM-cellulose | Mass recovery was more than 90% | ||
| Fused α-glucosidase | Heparin Sepharose | Bioactivity recovery was four times of dilution | 1996 | |
| Papilloma virus HPV16 E7MS2 fusion protein | Mono Q | 1994 | ||
| Lysozyme | Silica-based WCX | Activity recovery was approximately 100% | 2003 | |
| when initial protein concentration was up to 20 mg/mL | 2005 | |||
| Lysozyme | SP Sepharose | Activity recovery was approximately 95% when initial protein concentration was up to 40 mg/mL | 2002 | |
| Recombinant lysozyme | SP Sepharose FF | Activity recovery was approximately 100% when initial protein concentration was up to 4 mg/mL | 2002 | |
| Single-chain Fv-cellulose binding domain proteins | Cellulose | Refolding yield was 60% | 1999 | |
| rhG-CSF | Q Sepharose FF | Specific activity was 2.3 × 108 IU/mg, mass recovery was 43%, purity was 97% | 2005 | |
| Recombinant secretory leukocyte protease inhibitor | DEAE-cellulose | Protein concentration was enhanced 6.4-fold than dilution method, activity recovery was 46%, mass recovery was 96% | 1996 | |
| α-Lactoalbumin | Fractogel EMD DEAE | Refolding yield was 84% | 2005 | |
| CGTK10ase | SP Sepharose | The refolding yield was approximately 100% and the protein concentration after elution was 2.5 mg/mL | 2004 | |
| Recombinant LK68 | Q-Sepharose Hi-Trap | Refolding yield was 68%, which is 1.7-fold of dilution method | 2005 | |
| rhGH-GST | STREAMLINE DEAE | Refolding yield was 84% | 2002 | |
| EGFP | Q Hyper Z | Refolding yield was 90% | 2005 | |
| Recombinant dual human | DEAE Sepharose | Refolding yield was 19.46%, purity was 90% | 2005 | |
| Stem cell factor | FF |
Examples for protein refolding by AFC
| Proteins | Stationary phases | Refolding results | Years | References |
|---|---|---|---|---|
| Tublin | Immobilized GroEL | 1994 | ||
| (His)6-LECT2 | Ni-NTA | Refolding yields was 81% | 2003 | |
| (His)6-voltage-dependent anion-selective channel | Talon | 2003 | ||
| (His)6-aequorin | Ni-NTA | Specific activity was 2.2 × 1010 RLU/mg | 2003 | |
| (His)6-interleuin-15 receptor α-chain | Ni-NTA | Mass recovery was 6-fold of dilution method | 2003 | |
| Recombinant Toc75 | Ni-chelated Sepharose FF | 1998 | ||
| (His)6-exopolyphosphatase | Ni-chelated Sepharose FF | Mass recovery was 51% | 2003 | |
| Recombinant bovine prion | Ni-NTA | Mass recovery was 11% | 2003 | |
| Rv2430c | Ni-NTA | 2004 | ||
| Hsp-antigen fusion protein | Ni-agarose | Refolding yield was 34.5% | 2004 | |
| rhG-CSF | Cu-chelated | Specific activity was 2.3 × 108 IU-mg−1, mass recovery was 36.4% | 2004 | |
| Lysozyme | Immobilized liposome | Activity recovery was 100% | 2000 | |
| Bovine carbonic anhydrase | Immobilized liposome | Activity recovery was 83% | 1998 | |
| Lysozyme | Immobilized GroEL | Activity recovery was 81% | 2000 | |
| Fragment 450–650 of the spike protein of SARS-coronavirus | Ni-NTA | Mass recovery was 31.5% | 2005 | |
| rhIFN-γ | sht GroEL (191–345) | Mass recovery was 74.25% | 2006 | |
| IP10-scFv fusion protein | Ni-chelating | Refolding yield was 45% | 2006 |
Fig. 2Chromatogram of standard proteins separated by USRPP [7]. (a) USRPP with a dimensionless of 10 mm × 50 mm i.d., 1, cytochrome C; 2, myoglubin; 3, ribonuclease A; 4, lysozyme; 5, α-chymotrypsin; 6, α-mylase; 7, insulin. (b) USRPP with a dimensionless of 10 mm × 200 mm i.d., (1) cytochrome c; (2) myoglubin; (3) lysozyme; (4) α-amylase; (5) insulin.
Fig. 3Chromatogram of five standard proteins separated by Kelin® fast protein purification column [3] (1) cytochrome c; (2) myoglubin; (3) lysozyme; (4) α-amylase; (5) insulin.